卵巢 Brenner 瘤研究进展.

Ovarian Brenner tumor is a rare pathological type of ovarian tumor, which can be divided into benign, borderline/atypical proliferalive and malignant. Its etiology and pathogenesis are still unclear, the clinical manifestations and imaging examinations are not specific, and it is easy to misdiagnose before surgery, and the diagnosis mainly depends on postoperative pathological examination. Recent studies have found that malignant Brenner tumor (MBT) gradually progresses from benign Brenner tumor of the ovaries, and the process of occurrence is related to the genetic variants of fibroblast growth factor receptor 3 (FGFR3) gene, CCND1 gene, and murine double microbody gene 2 (MDM2), cyclin-dependent kinase inhibitor 2A (CDKN2A) gene and phosphoinositide 3-kinase catalytic alpha polypeptide (PIK3CA) gene. The treatment of ovarian Brenner tumor is mainly surgery, in which ovarian MBT can be supplemented with platinum-paclitaxel chemotherapy after surgery, and it is expected to be targeted therapy for its carcinogenic sites. Staging is an important prognostic factor, and early diagnosis and treatment is the key to improve prognosis. [ABSTRACT FROM AUTHOR]